Topline data from ORCA-1 trial expected in the Second Quarter of 2019
SEATTLE, Wash. and VANCOUVER, British Columbia, April 24, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the last study visit for the last subject enrolled in the ORCA-1 trial occurred on April 23, 2019. ORCA-1 topline efficacy and safety data are expected to be announced by the end of the second quarter.
ORCA-1 is the first in Achieve’s ORCA (Ongoing Research of Cytisinicline for Addiction) Program, which aims to evaluate the effectiveness of cytisinicline for smoking cessation and potentially other addiction indications. ORCA-1 was initiated in October 2018 and enrolled 254 smokers at eight centers across the United States. Importantly, the trial’s Data Safety Monitoring Committee met recently to conduct its final safety review and concluded there are no safety concerns for subjects or study conduct issues, and the trial should continue for completion.
Dr. Cindy Jacobs, Chief Medical Officer at Achieve commented, “Completing this trial represents a significant milestone in the cytisinicline development program and we continue to be impressed by the efficient conduct of our investigators and the commitment of the subjects who, like millions of people, are combatting nicotine addiction.”